Understanding Semaglutide vs Tirzepatide Science
Is Wegovy Semaglutide? Key Differences from Mounjaro
Yes, Wegovy contains semaglutide as its active pharmaceutical ingredient, making it a selective GLP-1 receptor agonist manufactured by Novo Nordisk. This differs fundamentally from Mounjaro, which contains tirzepatide and targets both GLP-1 and GIP receptors simultaneously. Understanding whether Wegovy is semaglutide helps clarify why these medications work through distinct pathways in your body. The semaglutide in Wegovy specifically mimics your natural GLP-1 hormone, whilst Mounjaro's tirzepatide activates an additional receptor system for glucose-dependent insulinotropic polypeptide.
When patients ask "is Wegovy semaglutide", they're often trying to understand which treatment mechanism might suit them better. Wegovy's semaglutide offers a well-established, single-target approach with extensive clinical data spanning several years. Mounjaro's dual-receptor approach represents newer science, approved more recently by the MHRA for weight management. Both require prescription-only medicine status and clinical assessment through our GPhC-registered service. Your prescriber can evaluate which mechanism aligns better with your medical history and treatment goals.
Wegovy vs Mounjaro Pricing and Bundle Options
Understanding that Wegovy is semaglutide helps explain our pricing structure, which reflects the different dosing schedules between these treatments. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25. Our bundles provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99.
Mounjaro follows a different pricing structure due to its distinct tirzepatide formulation and six-dose escalation schedule compared to Wegovy's five doses. Both treatments require the same rigorous clinical assessment and prescriber review process. Our Getting Started bundles like the Progress Duo (0.5mg & 1mg Wegovy) at £189.99 ensure seamless treatment progression. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering convenience rather than pure cost savings compared to individual purchases.
Clinical Evidence: Is Wegovy Semaglutide More Established?
The question "is Wegovy semaglutide" often relates to understanding its clinical foundation compared to Mounjaro's newer tirzepatide data. In the landmark STEP trials, patients taking Wegovy alongside diet and exercise achieved average weight reductions of approximately 15% at 68 weeks (Wilding et al., NEJM, 2021). The STEP programme encompassed over 4,500 participants across multiple studies, establishing semaglutide's efficacy profile in weight management.
Mounjaro's SURMOUNT trials demonstrated the potential of dual GIP+GLP-1 receptor activation, though direct comparison between trial results isn't appropriate due to different study designs and patient populations. Both medications underwent rigorous MHRA evaluation before UK approval, with NICE recommending both under specific clinical circumstances. The choice between Wegovy's established semaglutide profile and Mounjaro's innovative dual mechanism depends on individual clinical factors your prescriber will assess.
How Wegovy's Semaglutide Mechanism Works
Knowing that Wegovy is semaglutide helps explain its specific mechanism as a selective GLP-1 receptor agonist that mimics your body's natural incretin hormone. Semaglutide binds to GLP-1 receptors in your brain's appetite control centres, potentially reducing hunger signals and promoting earlier satiety after meals. This mechanism may help patients feel fuller with smaller portions and experience fewer food cravings throughout the day. The semaglutide in Wegovy also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Unlike Mounjaro's dual-receptor approach, Wegovy's semaglutide focuses exclusively on the GLP-1 pathway, providing a targeted intervention that's been extensively studied in weight management contexts.
Streamlined Ordering Process for Both Treatments
Whether you're interested in Wegovy because it contains semaglutide, or considering Mounjaro's tirzepatide alternative, our ordering process remains consistent across both treatments. Begin with our 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Our prescribers review your assessment within 3 working days (24 hours with express service), determining suitability for either Wegovy or Mounjaro based on clinical criteria. Once approved, we dispatch your medication via next-day delivery using cold-chain temperature-controlled packaging to maintain efficacy. Both treatments arrive with comprehensive injection guides and ongoing support through our clinical team. Our GPhC registration (#9012878) ensures professional pharmaceutical standards throughout your treatment journey.
Storage and Practical Considerations
Understanding that Wegovy is semaglutide reveals important storage advantages compared to Mounjaro's tirzepatide formulation. Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This makes Wegovy particularly convenient for travel or situations where refrigeration access is limited. Both medications arrive in pre-filled FlexTouch pens requiring weekly subcutaneous injection, typically in your abdomen, thigh, or upper arm. Wegovy's semaglutide formulation follows a structured dose escalation over 16 weeks, starting at 0.25mg and reaching 2.4mg maintenance dose. The pen design includes dose counters and safety features, making self-administration straightforward even for injection-naive patients.
Why Wegovy's Semaglutide vs Mounjaro's Dual Approach Matters
The fundamental difference in asking "is Wegovy semaglutide" centres on understanding single versus dual hormone receptor targeting for weight management. Wegovy's selective semaglutide approach offers predictable, well-characterised effects through isolated GLP-1 receptor activation. This focused mechanism may suit patients preferring established treatment pathways with extensive long-term safety data. Some prescribers favour this targeted approach for patients with specific medical histories or concurrent medications.
Conversely, Mounjaro's tirzepatide activates both GLP-1 and GIP receptors, potentially offering complementary effects on glucose metabolism and appetite regulation. This dual mechanism represents innovative pharmacology but with necessarily shorter long-term data compared to semaglutide's established profile. The choice between Wegovy's proven semaglutide pathway and Mounjaro's novel dual targeting depends entirely on individual clinical circumstances. Both remain prescription-only medicines requiring expert assessment to determine optimal treatment selection.
Making Your Choice: Both Available at EverydayMeds
Rather than wondering "is Wegovy semaglutide" and which option suits you better, our unique position offering both treatments means your prescriber can make evidence-based recommendations tailored to your circumstances. Complete your clinical assessment honestly, including any preferences between single-target (semaglutide) or dual-target (tirzepatide) approaches. Our prescribers consider factors including medical history, concurrent medications, lifestyle factors, and treatment goals when recommending between Wegovy and Mounjaro. Both treatments require identical commitment to reduced-calorie diet and increased physical activity for optimal outcomes. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment, using code FIRST40 for new customers or DOSE25 for returning patients at checkout.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
